CYBERDYNE (CYBQF) Stock Price & Analysis
CYBQF Stock Chart & Stats
- Day’s Range
- $1.39 - $1.39
- 52-Week Range
- $1.08 - $2.05
- Previous Close
- $1.39
- Volume
- N/A
- Average Volume (3M)
- 400
- Market Cap
- $257.97M
- Enterprise Value
- $37.03B
- Total Cash (Recent Filing)
- $13.12B
- Total Debt (Recent Filing)
- $540.00M
- Price to Earnings (P/E)
- 140.0
- Beta
- -0.29
- Next Earnings
- Nov 12, 2026 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Revenue Growth
The 70.2% TTM revenue increase indicates strong recent commercial expansion for CYBERDYNE’s medical and robotics offerings. If this growth persists, it can broaden installed usage, improve operating leverage, and support a larger base from which recurring device-related services may develop.
Gross Margin
A gross margin near 49% suggests CYBERDYNE’s products and related services retain meaningful economics after direct costs. This provides a foundation for improving profitability as revenue scales, although the company must still convert that gross profit into positive operating earnings.
Low Financial Leverage
Very low leverage gives CYBERDYNE substantial financial flexibility and limits the burden of interest and refinancing obligations. A conservative balance sheet can help fund commercialization, absorb periods of cash burn, and preserve strategic options while the business works toward stronger returns.
Bears Say
Negative Cash Flow
Negative operating and free cash flow show that current operations are consuming cash rather than funding the business internally. Continued cash burn could require use of balance-sheet resources and may constrain investment capacity if stronger cash conversion does not emerge.
Operating Losses
Negative EBIT and EBITDA margins indicate that CYBERDYNE has not yet covered its operating cost base despite strong reported revenue growth. This limits the durability of earnings, makes future profitability dependent on scaling or cost improvement, and increases execution risk.
Weak Returns On Capital
ROE of roughly 0.7% remains modest even after improving from prior negative periods, indicating that the company is generating limited profit from its capital base. Persistently low returns can reduce the effectiveness of reinvestment and signal that commercialization has yet to mature.
CYBERDYNE News
CYBQF FAQ
What was CYBERDYNE’s price range in the past 12 months?
What is CYBERDYNE’s market cap?
When is CYBERDYNE’s upcoming earnings report date?
How were CYBERDYNE’s earnings last quarter?
Is CYBERDYNE overvalued?
Does CYBERDYNE pay dividends?
What is CYBERDYNE’s EPS estimate?
How many shares outstanding does CYBERDYNE have?
What happened to CYBERDYNE’s price movement after its last earnings report?
Which hedge fund is a major shareholder of CYBERDYNE?
What is the TipRanks Smart Score and how is it calculated?
Company Description
CYBERDYNE
Headquartered in Tsukuba, Japan, and founded in 2004, CYBERDYNE Inc. is dedicated to the ongoing research, development, production, sales, leasing, and maintenance of sophisticated equipment and systems, primarily for the medical and defense sectors within Japan. Their innovative product line features the Hybrid Assistive Limb (HAL), available in medical variants for lower limbs and single joints, as well as non-medical versions designed for lower limbs, single joints, and lumbar support. The company also supplies HAL peripherals, robotic cleaners, and autonomous transport robots for factories, offices, and various other indoor environments. A notable technological offering is Acoustic X, a high-speed light pulse LED array that facilitates real-time photoacoustic imaging. Complementing their hardware, CYBERDYNE provides specialized treatments and programs such as Cybernics Treatment, which utilizes HAL to restore or enhance function for individuals suffering from conditions like spinal cord injuries, strokes, and neuromuscular disorders. They additionally offer HAL FIT and Neuro HALFIT to improve brain-nerve-musculoskeletal and general physical functions, respectively, and MTX Neuro HAL Plus to optimize brain-nerve performance in athletes. Furthermore, the company extends its expertise to critical areas including disaster rescue operations, heavy industrial labor assistance, and contributions to the entertainment industry.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Yoshiyuki Sankai
- Employees
- 203
- Website
- www.cyberdyne.jp
- Address
- 2-2-1, Gakuen-Minami, Tsukuba, IB, 305-0818, JP
CYBERDYNE (CYBQF) Earnings & Revenues
CYBQF Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 7 | 1 | 11 |
| Technical Analysis | 4 | 1 | 2 |
| Moving Averages | 3 | 0 | 9 |









